Horizon Therapeutics plc

05/02/2022 | Press release | Distributed by Public on 05/01/2022 23:08

Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)